Data gathered: November 22
AI Stock Analysis - Glaukos (GKOS)
Analysis generated September 30, 2024. Powered by Chat GPT.
Glaukos Corporation is a medical technology company focused on developing and commercializing novel ophthalmic products. The company's mission is to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) to deliver transformational outcomes for mild-to-moderate glaucoma patients. The company continues to advance a robust pipeline, including the expansion into new treatment modalities and further geographic markets.
Stock Alerts - Glaukos (GKOS)
 |
Glaukos | November 19 Price is up by 5.2% in the last 24h. |
|
Glaukos | November 6 Price is up by 5.4% in the last 24h. |
|
Glaukos | October 1 Employee Rating is down by 4.4% over the last month. |
|
Glaukos | October 1 Business Outlook among employees is down by 5.6% over the last month. |
Alternative Data for Glaukos
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 29 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 33,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | 43 | Sign up | Sign up | Sign up |
| Patents | 61 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 204 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,733 | Sign up | Sign up | Sign up |
| Instagram Followers | 3,085 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 815 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,635 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 869 | Sign up | Sign up | Sign up |
About Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
| Price | $144.00 |
| Target Price | Sign up |
| Volume | 548,320 |
| Market Cap | $7.8B |
| Year Range | $85.45 - $144.21 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Medical Devices |
In the news
 |
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?November 20 - Yahoo |
 |
Versor Investments LP Invests $457,000 in Glaukos Co. (NYSE:GKOS)November 15 - ETF Daily News |
Glaukos : Investor Presentation November 2024November 14 - Finnhub |
|
|
Amalgamated Bank Acquires 679 Shares of Glaukos Co. (NYSE:GKOS)November 12 - ETF Daily News |
Glaukos Announces Participation in Upcoming Investor ConferencesNovember 10 - Finnhub |
|
|
US Bancorp DE Has $733,000 Stake in Glaukos Co. (NYSE:GKOS)November 10 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 97M | 87M | 74M | -21M | -18M | -0.280 |
| Q2 '24 | 96M | 89M | 73M | -51M | -24M | -0.520 |
| Q1 '24 | 81M | 88M | 65M | -41M | -31M | -0.700 |
| Q4 '23 | 81M | 91M | 63M | -37M | -25M | -0.630 |
| Q3 '23 | 75M | 73M | 60M | -30M | -21M | -0.500 |
Insider Transactions View All
| Kliman Gilbert H filed to sell 32,336 shares at $130. September 11 '24 |
| Kliman Gilbert H filed to sell 33,336 shares at $131. September 11 '24 |
| Gilliam Joseph E filed to sell 102,169 shares at $130. August 23 '24 |
| Gilliam Joseph E filed to sell 102,749 shares at $129.3. August 23 '24 |
| Stapley Marc filed to sell 34,076 shares at $126.9. August 19 '24 |
Similar companies
Read more about Glaukos (GKOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Glaukos?
The Market Cap of Glaukos is $7.8B.
What is the current stock price of Glaukos?
Currently, the price of one share of Glaukos stock is $144.00.
How can I analyze the GKOS stock price chart for investment decisions?
The GKOS stock price chart above provides a comprehensive visual representation of Glaukos' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Glaukos shares. Our platform offers an up-to-date GKOS stock price chart, along with technical data analysis and alternative data insights.
Does GKOS offer dividends to its shareholders?
As of our latest update, Glaukos (GKOS) does not offer dividends to its shareholders. Investors interested in Glaukos should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Glaukos?
Some of the similar stocks of Glaukos are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.